• IFAPP

    Established in 1975, IFAPP works to advance the discipline of Pharmaceutical Medicine and Medicines Development as a profession to the benefit of patients and Public Health worldwide.

Read More..

Bangladesh: Partnership opportunities

Overview

The pharmaceutical industry is one of the most dynamic and powerful sectors in Bangladesh.  It is technologically one of the most developed manufacturing industries and currently contributes about one percent to total GDP with great potential for expansion.  Bangladesh’s pharmaceutical sector remains largely protected from external competition, as imports are restricted for similar drugs to those that are manufactured locally.  The World Trade Organization's (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPs) agreement permits Bangladesh to reverse-engineer patented generic pharmaceutical products to sell locally and export to markets around the world.

The TRIPs agreement is turning Bangladesh into a hub for affordable and high-quality generic medicines and contract manufacturing, with exports to potentially more than 120 countries across the world.  More than ten leading Bangladeshi pharmaceutical companies are exporting generics to international markets.  Bangladeshi pharmaceutical companies are investing heavily in upgrading manufacturing plants and obtaining certifications from the United States, Australia, Canada and Europe.  Beximco Pharma and Square Pharma both successfully completed FDA inspection of their oral solid dosage manufacturing facilities and received notification in June 2015.  The top-ranking companies have already developed world-class pharmaceutical plants with state-of-the-art technology.

Bangladeshi pharmaceutical companies focus primarily on branded generic final formulations, using both imported and domestically produced Active Pharmaceutical Ingredients (APIs).  About 85 percent of the drugs sold in Bangladesh are generic and 15 percent are patented drugs.  Bangladesh manufactures a wide range of products from anti-ulcerates, flouroquinolones, anti-rheumatic non-steroid drugs, non-narcotic analgesics, antihistamines, and oral anti-diabetic drugs.  Bangladesh also produces high-tech medicines such as anticancer treatments, hormonal products, enzymes and coenzymes on a limited scale.

There are currently around 200 Bangladeshi pharmaceutical companies in operation.  The industry is highly concentrated as the top 20 companies generate 85 percent of the revenue.  The top ten manufacturers by share of market revenue are as follows:  Square (19 percent), Incepta (9.5 percent), Beximco (9 percent), Opsonin (5 percent), Renata (4.9 percent), Eskayef (4.7 percent), ACI (4.3 percent), ACME (4.1 percent), Aritstopharma (4 percent), and Drug International (3.7 percent).  Local manufacturers dominate the industry, enjoying about 90 percent market share while multinationals hold 10 percent.

Opportunities

Multinational and large national companies generally follow current good manufacturing practices (cGMP) including rigorous quality control of their products.  This offers significant opportunities for overseas firms to partner with Bangladeshi companies to produce for domestic or international markets.  The pharmaceutical market trend is shifting toward unconventional drugs where there is greater opportunity for foreign investment.  The areas of primary demand are:

  • Veterinary and human vaccines;
  • Drug development and contract research outsourcing from European countries, including the United Kingdom.  Examples include ophthalmic pharmaceuticals and cardio-vascular medication;
  • Clinical trials of new pharmaceuticals;
  • Biological drugs (for instance, insulin and hepatitis);
  • Disease modifying drugs (for instance, anti-cancer medications);
  • Hormonal therapies.

Bangladesh Association of Pharmaceutical Physicians (BAPP)

BAPP was founded in 2007 and it got membership in IFAPP in 2011. Dr. Hasan Mahmood is the founder president. Currently BAPP has 25 members. Most of the members are working in marketing sector. BAPP currently working to attract FDI in the clinical trial sector.

panels_data:
a:3:{s:7:"widgets";a:4:{i:0;a:13:{s:5:"image";i:3605;s:14:"image_fallback";s:0:"";s:4:"size";s:4:"full";s:5:"align";s:7:"default";s:5:"title";s:0:"";s:14:"title_position";s:6:"hidden";s:3:"alt";s:0:"";s:3:"url";s:0:"";s:5:"bound";b:1;s:12:"_sow_form_id";s:13:"581adc0357764";s:10:"new_window";b:0;s:10:"full_width";b:0;s:11:"panels_info";a:7:{s:5:"class";s:30:"SiteOrigin_Widget_Image_Widget";s:3:"raw";b:0;s:4:"grid";i:0;s:4:"cell";i:0;s:2:"id";i:0;s:9:"widget_id";s:36:"fb81bc7a-4f00-4820-af97-7b92b5578097";s:5:"style";a:1:{s:18:"background_display";s:4:"tile";}}}i:1;a:4:{s:5:"title";s:0:"";s:4:"text";s:327:"";s:6:"filter";b:0;s:11:"panels_info";a:7:{s:5:"class";s:14:"WP_Widget_Text";s:3:"raw";b:0;s:4:"grid";i:0;s:4:"cell";i:0;s:2:"id";i:1;s:9:"widget_id";s:36:"193651cc-b478-477d-ba9e-fdf4cfe69e7c";s:5:"style";a:1:{s:18:"background_display";s:4:"tile";}}}i:2;a:6:{s:5:"title";s:0:"";s:4:"text";s:4041:"Overview The pharmaceutical industry is one of the most dynamic and powerful sectors in Bangladesh.  It is technologically one of the most developed manufacturing industries and currently contributes about one percent to total GDP with great potential for expansion.  Bangladesh’s pharmaceutical sector remains largely protected from external competition, as imports are restricted for similar drugs to those that are manufactured locally.  The World Trade Organization's (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPs) agreement permits Bangladesh to reverse-engineer patented generic pharmaceutical products to sell locally and export to markets around the world. The TRIPs agreement is turning Bangladesh into a hub for affordable and high-quality generic medicines and contract manufacturing, with exports to potentially more than 120 countries across the world.  More than ten leading Bangladeshi pharmaceutical companies are exporting generics to international markets.  Bangladeshi pharmaceutical companies are investing heavily in upgrading manufacturing plants and obtaining certifications from the United States, Australia, Canada and Europe.  Beximco Pharma and Square Pharma both successfully completed FDA inspection of their oral solid dosage manufacturing facilities and received notification in June 2015.  The top-ranking companies have already developed world-class pharmaceutical plants with state-of-the-art technology. Bangladeshi pharmaceutical companies focus primarily on branded generic final formulations, using both imported and domestically produced Active Pharmaceutical Ingredients (APIs).  About 85 percent of the drugs sold in Bangladesh are generic and 15 percent are patented drugs.  Bangladesh manufactures a wide range of products from anti-ulcerates, flouroquinolones, anti-rheumatic non-steroid drugs, non-narcotic analgesics, antihistamines, and oral anti-diabetic drugs.  Bangladesh also produces high-tech medicines such as anticancer treatments, hormonal products, enzymes and coenzymes on a limited scale. There are currently around 200 Bangladeshi pharmaceutical companies in operation.  The industry is highly concentrated as the top 20 companies generate 85 percent of the revenue.  The top ten manufacturers by share of market revenue are as follows:  Square (19 percent), Incepta (9.5 percent), Beximco (9 percent), Opsonin (5 percent), Renata (4.9 percent), Eskayef (4.7 percent), ACI (4.3 percent), ACME (4.1 percent), Aritstopharma (4 percent), and Drug International (3.7 percent).  Local manufacturers dominate the industry, enjoying about 90 percent market share while multinationals hold 10 percent. Opportunities Multinational and large national companies generally follow current good manufacturing practices (cGMP) including rigorous quality control of their products.  This offers significant opportunities for overseas firms to partner with Bangladeshi companies to produce for domestic or international markets.  The pharmaceutical market trend is shifting toward unconventional drugs where there is greater opportunity for foreign investment.  The areas of primary demand are:
  • Veterinary and human vaccines;
  • Drug development and contract research outsourcing from European countries, including the United Kingdom.  Examples include ophthalmic pharmaceuticals and cardio-vascular medication;
  • Clinical trials of new pharmaceuticals;
  • Biological drugs (for instance, insulin and hepatitis);
  • Disease modifying drugs (for instance, anti-cancer medications);
  • Hormonal therapies.
Bangladesh Association of Pharmaceutical Physicians (BAPP) BAPP was founded in 2007 and it got membership in IFAPP in 2011. Dr. Hasan Mahmood is the founder president. Currently BAPP has 25 members. Most of the members are working in marketing sector. BAPP currently working to attract FDI in the clinical trial sector.

";s:20:"text_selected_editor";s:4:"html";s:5:"autop";b:1;s:12:"_sow_form_id";s:13:"581aece8d4f90";s:11:"panels_info";a:7:{s:5:"class";s:31:"SiteOrigin_Widget_Editor_Widget";s:3:"raw";b:0;s:4:"grid";i:1;s:4:"cell";i:1;s:2:"id";i:2;s:9:"widget_id";s:36:"c7ad20fc-0f04-4264-9d3d-77a3ba21ba9b";s:5:"style";a:1:{s:18:"background_display";s:4:"tile";}}}i:3;a:6:{s:5:"title";s:0:"";s:4:"text";s:22:"[widget id="search-2"]";s:20:"text_selected_editor";s:4:"html";s:5:"autop";b:1;s:12:"_sow_form_id";s:13:"581af4b710ab3";s:11:"panels_info";a:7:{s:5:"class";s:31:"SiteOrigin_Widget_Editor_Widget";s:3:"raw";b:0;s:4:"grid";i:1;s:4:"cell";i:2;s:2:"id";i:3;s:9:"widget_id";s:36:"b1ec6397-34ad-40dd-b4cd-d89b5b22dd6f";s:5:"style";a:1:{s:18:"background_display";s:4:"tile";}}}}s:5:"grids";a:2:{i:0;a:2:{s:5:"cells";i:1;s:5:"style";a:0:{}}i:1;a:2:{s:5:"cells";i:3;s:5:"style";a:2:{s:7:"padding";s:17:"0px 60px 0px 60px";s:18:"background_display";s:4:"tile";}}}s:10:"grid_cells";a:4:{i:0;a:2:{s:4:"grid";i:0;s:6:"weight";i:1;}i:1;a:2:{s:4:"grid";i:1;s:6:"weight";d:0.1564811818253399877676201867870986461639404296875;}i:2;a:2:{s:4:"grid";i:1;s:6:"weight";d:0.5846076210391799587995365072856657207012176513671875;}i:3;a:2:{s:4:"grid";i:1;s:6:"weight";d:0.258911197135479997921692074669408611953258514404296875;}}}

IFAPP

INTERNATIONAL FEDERATION OF ASSOCIATIONS OF PHARMACEUTICAL PHYSICIANS & PHARMACEUTICAL MEDICINE

Log In

Create an account